HPV18 DNA levels are not prognostic for precancerous cervical lesions

Jan 27, 2009

Perhaps surprisingly, the number of copies of the carcinogenic human papillomavirus type 18 (HPV18) relative to cellular DNA is not associated with the likelihood of progression to advanced precancerous lesions of the cervix, according to a study in the January 27 online issue of the Journal of the National Cancer Institute.

Two types of HPV are most frequently associated with cervical cancer, HPV16 and HPV18. Previous studies showed that the number of HPV16 copies per cell correlated with an increasing risk of progression to cervical intraepithelial neoplasia grade 2 or 3 (CIN2-3). The prognostic significance of HPV18 DNA level is not known.

In the current study, Long Fu Xi, M.D, Ph.D., of the University of Washington in Seattle, and colleagues compared the number of copies of HPV18 DNA relative to cellular DNA at baseline with a woman's risk of progressing to CIN2-3. The 303 study participants were drawn from the Atypical Squamous Cells of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study.

During the 2-year study period, 92 women were diagnosed with CIN2-3. Among women with a cytologic diagnosis of low- or high-grade squamous intraepithelial lesions at enrollment, HPV18 DNA level was lower in women with CIN2-3 than those without CIN2-3.

"In summary, our data indicated that HPV18 DNA levels were highest among women with evidence of a benign squamous intraepithelial lesion, intermediate among those with CIN2-3, and lowest among those with normal cytological findings," the authors write. "Thus, testing for high levels of HPV18 DNA does not appear to be clinically useful."

In an accompanying editorial, Eduardo Franco, Dr.P.H., and François Coutlée, M.D., of McGill University in Montreal, agree with the authors' conclusion and applaud their effort to elucidate the underlying biology of cervical cancer. "As far as clinical practice is concerned, the obvious conclusion from the study of Xi et al. is that quantifying the HPV18 DNA load may not have the same value as for HPV16," the editorialists write. "That said, the findings from this study considerably extend our appreciation for the heterogeneity of molecular events and their cellular targets in cervical carcinogenesis."

Citations:

• Article: Xi LF et al. Human Papillomavirus Type 18 DNA Load and 2-Year Cumulative Diagnoses of Cervical Intraepithelial Neoplasia Grades 2-3. J Natl Cancer Inst 2009;101:153-61.
• Editorial: Franco E and Coutlee, F. Prognostic Value of Measuring Load of Human Papillomavirus DNA in Cervical Samples: An Elusive Target. J Natl Cancer Inst 2009;101:131-3.

Source: Journal of the National Cancer Institute

Explore further: Exercising restraint to stall tumor growth

add to favorites email to friend print save as pdf

Related Stories

Molecular pathology via IR and Raman spectral imaging

Dec 10, 2013

IR and Raman spectral imaging can distinguish between tissue types, disease types and stages, and even identify the primary tumors from spectral patterns observed in metastatic cells. Furthermore, these techniques ...

A possible cause -- and cure -- for genital cancer in horses?

Dec 20, 2010

Horses, like humans, suffer from genital cancer. Work by Sabine Brandt and colleagues at the University of Veterinary Medicine, Vienna -- together with Tim Scase and with Alastair Foote and his group -- provides strong evidence ...

Recommended for you

Exercising restraint to stall tumor growth

24 minutes ago

Many proteins undergo an assembly line-style process of glycosylation as they travel from a cellular structure called the endoplasmic reticulum (ER) to the Golgi apparatus and on through its various compartments, ...

New tool to probe cancer's molecular make-up

23 hours ago

Scientists have shown how to better identify and measure vital molecules that control cell behaviour – paving the way for improved tools for diagnosis, prediction and monitoring of cancer.

Mayo Clinic offers at-home colon cancer test

Aug 26, 2014

Mayo Clinic is taking another step toward making detection of colorectal cancer as convenient as possible, announcing Monday an at-home kit that arrives and is sent back in the mail, stool sample included.

User comments : 0